Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections
Goeun Choi,Huiyan Piao,N. Sanoj Rejinold,Seungjin Yu,Ki-yeok Kim,Geun-woo Jin,Jin-Ho Choy,Jin-Ho Choy +7 more
Reads0
Chats0
TLDR
In this paper, a NIC-loaded hydrotalcite composite nanohybrids were further coated with Tween 60 or hydroxypropyl methyl cellulose (HPMC), and characterized them in vitro.Abstract:
COVID-19 has been affecting millions of individuals worldwide and, thus far, there is no accurate therapeutic strategy. This critical situation necessitates novel formulations for already existing, FDA approved, but poorly absorbable drug candidates, such as niclosamide (NIC), which is of great relevance. In this context, we have rationally designed NIC-loaded hydrotalcite composite nanohybrids, which were further coated with Tween 60 or hydroxypropyl methyl cellulose (HPMC), and characterized them in vitro. The optimized nanohybrids showed particle sizes <300 nm and were orally administrated to rats to determine whether they could retain an optimum plasma therapeutic concentration of NIC that would be effective for treating COVID-19. The pharmacokinetic (PK) results clearly indicated that hydrotalcite-based NIC formulations could be highly potential options for treating the ongoing pandemic and we are on our way to understanding the in vivo anti-viral efficacy sooner. It is worth mentioning that hydrotalcite-NIC nanohybrids maintained a therapeutic NIC level, even above the required IC50 value, after just a single administration in 8-12 h. In conclusion, we were very successfully able to develop a NIC oral formulation by immobilizing with hydrotalcite nanoparticles, which were further coated with Tween 60 or HPMC, in order to enhance their emulsification in the gastrointestinal tract.read more
Citations
More filters
Journal ArticleDOI
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments
Niaz Uddin Mahmud,Muzahidul Islam Anik,M. Khalid Hossain,Md. Ishak Khan,S. M. Naim Uddin,M. Ashrafuzzaman,Mushfiqur Rahaman +6 more
TL;DR: This unique mini-review aims to compile and elaborate on the recent advances of nanobased approaches from prevention, diagnostics, treatment to vaccine developments against SARS-CoV-2, and associated challenges.
Journal ArticleDOI
Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19.
TL;DR: In this article, a simple self-assembling technique through which Zein nanoparticles were successfully used to encapsulate NIC, which was then coated with bovine serum albumin (BSA) in order to improve the drugs' stability, injectablity, and selectivity towards the virus-infected cells.
Journal ArticleDOI
Mucoadhesive nanoformulations and their potential for combating COVID-19.
Journal ArticleDOI
Niclosamide-exfoliated anionic clay nanohybrid repurposed as an antiviral drug for tackling covid-19; oral formulation with tween 60/eudragit s100.
TL;DR: In this paper, the loading of NIC into exfoliated layered double hydroxide nanoparticles (X-LDH NPs) was explored, and the final product was modified with eudragit S100 (ES100), an enteric coating polymer, to improve absorption by the gastro/intestinal tract.
Journal ArticleDOI
Niclosamide-loaded nanoparticles disrupt Candida biofilms and protect mice from mucosal candidiasis
Yogesh B. Sutar,Sunna Nabeela,Shakti Pal Singh,Abdullah Alqarihi,Norma V. Solis,Teklegiorgis Ghebremariam,Scott G. Filler,Ashraf S. Ibrahim,Abhijit A. Date,Priya Uppuluri +9 more
TL;DR: This is the first study that targets biofilm detachment as a target to get rid of drug-resistant Candida biofilms and uses NPs of an FDA-approved nontoxic drug to improve biofilm penetrability and microbial killing.
References
More filters
Journal ArticleDOI
Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.
Ka Shing Cheung,Ivan Hung,Pierre P.Y. Chan,Kwok-Cheung Lung,Eugene Tso,Raymond W. Liu,Yuk-Yung Ng,Man Y. Chu,Tom Wai-Hin Chung,Anthony Raymond Tam,Cyril C. Y. Yip,Kit-Hang Leung,Agnes Yim Fong Fung,Ricky Ruiqi Zhang,Yansheng Lin,Ho Ming Cheng,Anna J. X. Zhang,Kelvin K. W. To,Kwok H. Chan,Kwok-Yung Yuen,Wai K. Leung +20 more
TL;DR: A systematic review and meta-analysis of published gastrointestinal symptoms and detection of virus in stool, and a analysis of data from a cohort of patients with COVID-19 in Hong Kong found that 17.6% of patientsWith CO VID-19 had gastrointestinal symptoms, and healthcare workers should exercise caution in collecting fecal samples or performing endoscopic procedures in patients with CoV-2—even during patient recovery.
Journal ArticleDOI
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
Eskild Petersen,Eskild Petersen,Marion Koopmans,Unyeong Go,Davidson H. Hamer,Nicola Petrosillo,Francesco Castelli,Merete Storgaard,Sulien Al Khalili,Lone Simonsen,Lone Simonsen +10 more
TL;DR: Compared with other epidemic coronaviruses, SARS-CoV-2 causes mild or asymptomatic disease in most cases; however, severe to critical illness occurs in a small proportion of infected individuals, with the highest rate seen in people older than 70 years.
Journal ArticleDOI
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Sangeun Jeon,Meehyun Ko,Jihye Lee,Inhee Choi,Soo Young Byun,Soonju Park,David Shum,Seungtaek Kim +7 more
TL;DR: 24 potential antiviral drug candidates against SARS-CoV-2 infection are identified and two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.
Journal ArticleDOI
SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection
Nils C. Gassen,Daniela Niemeyer,Doreen Muth,Victor M. Corman,Silvia Martinelli,Alwine Gassen,Kathrin Hafner,Jan Papies,Kirstin Mösbauer,Andreas Zellner,Anthony S. Zannas,Alexander M. Herrmann,Florian Holsboer,Ruth Brack-Werner,Michael Boshart,Bertram Müller-Myhsok,Bertram Müller-Myhsok,Christian Drosten,Marcel A. Müller,Theo Rein,Theo Rein +20 more
TL;DR: It is shown that S-phase kinase-associated protein 2 (SKP2) is responsible for lysine-48-linked poly-ubiquitination of beclin 1, resulting in its proteasomal degradation, and that inhibition of SKP2 enhances autophagy and reduces replication of MERS coronavirus.
Journal ArticleDOI
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
TL;DR: A brief review of the broad antiviral activity of niclosamide is summarized and its potential clinical use in the treatment of COVID-19 is highlighted.